Increase/Decrease in Cash: The total change in cash for the company over the given period.
Enliven Therapeutics, Inc. (ELVN) had Increase/Decrease in Cash of $-22.44M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-20.15M |
|
-- |
|
-- |
|
$25.10M |
|
$-25.10M |
|
$4.95M |
|
$-20.15M |
|
$-20.15M |
|
$-20.15M |
|
$-20.15M |
|
$-20.15M |
|
$-20.15M |
|
$-25.10M |
|
$-25.34M |
|
62.09M |
|
62.09M |
|
$-0.32 |
|
$-0.32 |
|
| Balance Sheet Financials | |
$482.68M |
|
$0.40M |
|
$8.19M |
|
$490.88M |
|
$14.65M |
|
-- |
|
$0.10M |
|
$14.75M |
|
$476.12M |
|
$476.12M |
|
$476.12M |
|
59.26M |
|
| Cash Flow Statement Financials | |
$-54.46M |
|
$-186.22M |
|
$218.24M |
|
$124.17M |
|
$101.73M |
|
|
Increase/Decrease in Cash |
$-22.44M |
$21.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
32.95 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-54.62M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-4.23% |
|
-4.23% |
|
-4.10% |
|
-4.23% |
|
$8.03 |
|
$-0.88 |
|
$-0.88 |
|